• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes.

作者信息

Mitroulis Ioannis, Papadopoulos Vasileios, Lamprianidou Eleftheria, Mirtschink Peter, Liapis Konstantinos, Zafeiropoulou Kalliopi, Kourakli Alexandra, Moysiadis Theodoros, Papoutselis Menelaos, Vrachiolias George, Symeonidis Argiris, Kotsianidis Ioannis

机构信息

Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.

Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany.

出版信息

Blood Cancer J. 2023 May 3;13(1):64. doi: 10.1038/s41408-023-00844-4.

DOI:10.1038/s41408-023-00844-4
PMID:37137883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10156800/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd8c/10156800/fb9ea97ee007/41408_2023_844_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd8c/10156800/fb9ea97ee007/41408_2023_844_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd8c/10156800/fb9ea97ee007/41408_2023_844_Fig1_HTML.jpg

相似文献

1
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes.常见的心血管生物标志物可独立预测骨髓增生异常综合征患者的预后。
Blood Cancer J. 2023 May 3;13(1):64. doi: 10.1038/s41408-023-00844-4.
2
Clinical and genetic predictors of prognosis in myelodysplastic syndromes.骨髓增生异常综合征预后的临床和遗传预测指标
Haematologica. 2014 Jun;99(6):956-64. doi: 10.3324/haematol.2013.085217.
3
[Molecular Markers of Prognosis in Myelodysplastic Syndromes--Review].[骨髓增生异常综合征预后的分子标志物——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):285-9. doi: 10.7534/j.issn.1009-2137.2016.01.055.
4
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.伴有骨髓增生异常综合征的 IDH1 基因突变与不良预后相关。
Haematologica. 2010 Oct;95(10):1668-74. doi: 10.3324/haematol.2010.025494. Epub 2010 May 21.
5
Prognosis of myelodysplastic syndromes.骨髓增生异常综合征的预后。
Hematology Am Soc Hematol Educ Program. 2010;2010:330-7. doi: 10.1182/asheducation-2010.1.330.
6
Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia.骨髓增生异常综合征和慢性粒单核细胞白血病中的自身抗体。
Leuk Lymphoma. 2019 Oct;60(10):2594-2596. doi: 10.1080/10428194.2019.1599114. Epub 2019 Apr 8.
7
WT1 Expression in Patients with Myelodysplastic Syndromes: A Variety of Possibilities in Future Clinical Practice.WT1在骨髓增生异常综合征患者中的表达：未来临床实践中的多种可能性
Acta Haematol. 2017;137(1):30-31. doi: 10.1159/000449363. Epub 2016 Nov 22.
8
Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment.骨髓增生异常综合征的分子病理学：新进展及其对诊断和治疗的意义
Leuk Lymphoma. 2015;56(11):3022-30. doi: 10.3109/10428194.2015.1037756. Epub 2015 May 26.
9
Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.预测接受阿扎胞苷治疗的高危骨髓增生异常综合征患者的结局。
Epigenomics. 2021 Jul;13(14):1129-1143. doi: 10.2217/epi-2021-0124. Epub 2021 Jul 22.
10
[Myelodysplastic syndromes: clinically relevant aspects in diagnosis, prognosis and prediction].[骨髓增生异常综合征：诊断、预后及预测方面的临床相关要点]
Dtsch Med Wochenschr. 2008 Oct;133(41):2086-90. doi: 10.1055/s-0028-1091249. Epub 2008 Oct 1.

引用本文的文献

1
Characterization of the Molecular Signature of Human Monocytes in Aging and Myelodysplastic Neoplasms.衰老和骨髓增生异常综合征中人类单核细胞分子特征的表征
Eur J Immunol. 2025 Jan;55(1):e202451387. doi: 10.1002/eji.202451387. Epub 2024 Nov 8.

本文引用的文献

1
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
2
Clonal hematopoiesis and inflammation - the perpetual cycle.克隆性造血与炎症——永恒的循环。
Trends Cell Biol. 2023 Aug;33(8):695-707. doi: 10.1016/j.tcb.2022.12.001. Epub 2022 Dec 31.
3
Clonal hematopoiesis, multi-omics and coronary artery disease.克隆性造血、多组学与冠状动脉疾病。
Nat Cardiovasc Res. 2022;1(11):965-967. doi: 10.1038/s44161-022-00154-1. Epub 2022 Nov 2.
4
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.低危骨髓增生异常综合征（MDS）患者的死亡原因及超额死亡率：来自欧洲MDS登记处的报告
Br J Haematol. 2023 Feb;200(4):451-461. doi: 10.1111/bjh.18542. Epub 2022 Nov 6.
5
Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease.克隆性造血不定潜能、DNA 甲基化与冠状动脉疾病风险。
Nat Commun. 2022 Sep 12;13(1):5350. doi: 10.1038/s41467-022-33093-3.
6
Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: is there an association?心血管疾病相关循环生物标志物与癌症发病率和死亡率：两者之间存在关联吗？
Cardiovasc Res. 2022 Jul 27;118(10):2317-2328. doi: 10.1093/cvr/cvab282.
7
Current challenges and unmet medical needs in myelodysplastic syndromes.骨髓增生异常综合征的当前挑战和未满足的医疗需求。
Leukemia. 2021 Aug;35(8):2182-2198. doi: 10.1038/s41375-021-01265-7. Epub 2021 May 28.
8
Myelodysplastic Syndromes.骨髓增生异常综合征
N Engl J Med. 2020 Oct 1;383(14):1358-1374. doi: 10.1056/NEJMra1904794.
9
A population-based study of cardiovascular disease mortality risk in US cancer patients.基于人群的美国癌症患者心血管疾病死亡风险研究。
Eur Heart J. 2019 Dec 21;40(48):3889-3897. doi: 10.1093/eurheartj/ehz766.
10
Heart Failure Stimulates Tumor Growth by Circulating Factors.心力衰竭通过循环因子刺激肿瘤生长。
Circulation. 2018 Aug 14;138(7):678-691. doi: 10.1161/CIRCULATIONAHA.117.030816.